1. Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009 
S. Di Giambenedetto, M. Prosperi, I. Fanti, B. Bruzzone, S. Paolucci, G. Penco, G. Meini, A. Di Biagio, E. Paolini, V. Micheli, P. Meraviglia, P. Castelli, P. Corsi, A. Gonnelli, M. Fabbiani, M. Zazzi, A. De Luca 
Clinical Microbiology and Infection 
Volume 17, Issue 9, Pages (September 2011)
DOI: /j x
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
(a) Evolution of antiretroviral drug usage in failing regimens from 2007 to (b) Evolution of the prevalence of resistance (at least one major IAS-2009 mutation) to any nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI) and non-B subtypes by calendar year from 2007 to n, number of cases used as denominator; TA, thymidine analogues (zidovudine/stavudine); Non-TA, (abacavir/didanosine/tenofovir); rtv, ritonavir; FI, fusion inhibitor; EI, entry inhibitor; INI, Integrose inhibitor.
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2011 European Society of Clinical Infectious Diseases Terms and Conditions